Most Read Articles
26 Mar 2021
Women aged <40 years with alcohol-associated liver disease (ALD) remain at risk of mortality beyond 1 year after liver transplantation (LT), and the most common cause of death was recurrent disease or explicit mention of alcohol, a study has found.
Jairia Dela Cruz, 05 Apr 2021
In the treatment of patients with gram-positive hospital-acquired or ventilator-associated bacterial pneumonia, tedizolid works as well as linezolid in terms of 28-day all-cause mortality but not investigator-assessed clinical response, according to the results of a phase III trial.
6 days ago
Renin-angiotensin system (RAS) inhibitors appear to protect against major adverse cardiovascular events after coronary artery bypass grafting (CABG), whether or not patients had an indication for treatment, a recent study has shown.
Tristan Manalac, 3 days ago
The beneficial effects of metabolic bariatric surgery are long-lasting, with improvements in renal function and reductions in albuminuria still apparent 1 year after the procedure, according to a Singapore study presented at the recently concluded ENDO 2021 virtual conference by the Endocrine Society.

Product Highlight - Amgevita

31 Mar 2021
Backed by Amgen’s 40 years of experience in biologics, the first adalimumab biosimilar approved in Hong Kong1

• Proven clinical similarity to RP* adalimumab in 2 phase III studies2,3

• Demonstrated similar Safety and Immunogenicity profile to RP in Head-to-Head studies2,3

• Citrate-free formulation4


Also available in pre-filled syringe
*RP: reference product


References:
1. Department of Health. Drug Office [Online]. Available at: www.drugoffice.gov.hk/eps/do/en/healthcare_providers/home.html.
2. Cohen S, Genovese MC, et al. Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study. Ann Rheum Dis 2017; 76(10): 1679-1687.
3. Papp K, Bachelez H, et al. Clinical similarity of biosimilar ABP 501 to adalimumab in the treatment of patients with moderate to severe plaque psoriasis: A randomized, double-blind, multicenter, phase III study. J Am Acad Dermatol 2017; 76(6): 1093-1102.
4. Amgevita HK prescribing information [version: May 2020].

Related MIMS Drugs

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Hong Kong digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
26 Mar 2021
Women aged <40 years with alcohol-associated liver disease (ALD) remain at risk of mortality beyond 1 year after liver transplantation (LT), and the most common cause of death was recurrent disease or explicit mention of alcohol, a study has found.
Jairia Dela Cruz, 05 Apr 2021
In the treatment of patients with gram-positive hospital-acquired or ventilator-associated bacterial pneumonia, tedizolid works as well as linezolid in terms of 28-day all-cause mortality but not investigator-assessed clinical response, according to the results of a phase III trial.
6 days ago
Renin-angiotensin system (RAS) inhibitors appear to protect against major adverse cardiovascular events after coronary artery bypass grafting (CABG), whether or not patients had an indication for treatment, a recent study has shown.
Tristan Manalac, 3 days ago
The beneficial effects of metabolic bariatric surgery are long-lasting, with improvements in renal function and reductions in albuminuria still apparent 1 year after the procedure, according to a Singapore study presented at the recently concluded ENDO 2021 virtual conference by the Endocrine Society.